000			01588 a2200433 4500
005			20250517111732.0
264		0	_c20160831
008			201608s 0 0 rus d
022			_a0023-2149
040			_aNLM _beng _cNLM
100	1		_aOgurtsov, P P
245	0	0	_a[PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C]. _h[electronic resource]
260			_bKlinicheskaia meditsina _c2016
300			_a224-30 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAdult
650	0	4	_aAntiviral Agents _xtherapeutic use
650	0	4	_aBlood Group Antigens _xanalysis
650	0	4	_aDrug Therapy, Combination _xmethods
650	0	4	_aFemale
650	0	4	_aHepacivirus _xdrug effects
650	0	4	_aHepatitis C, Chronic _xcomplications
650	0	4	_aHumans
650	0	4	_aInterferon-alpha _xtherapeutic use
650	0	4	_aInterferons
650	0	4	_aInterleukins _xgenetics
650	0	4	_aLiver Cirrhosis _xetiology
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPolyethylene Glycols _xtherapeutic use
650	0	4	_aPolymorphism, Genetic
650	0	4	_aPredictive Value of Tests
650	0	4	_aPrognosis
650	0	4	_aRecombinant Proteins _xtherapeutic use
650	0	4	_aReproducibility of Results
650	0	4	_aRibavirin _xtherapeutic use
700	1		_aKukhareva, E I
773	0		_tKlinicheskaia meditsina _gvol. 94 _gno. 3 _gp. 224-30
999			_c26326336 _d26326336